Skip to main content
Premium Trial:

Request an Annual Quote

MediSapiens, Bayer Developing Platform for Cancer Genomic Data Analysis

NEW YORK (GenomeWeb News) – MediSapiens today announced that it and Bayer HealthCare Pharmaceuticals have reached an agreement to develop a platform for the analysis of cancer genomics data.

"Genomics data is increasingly used both in preclinical and clinical research, but lacks software tools that can be adapted to various research environments," Tommi Pisto, CEO of MediSapiens, said in a statement. "Our flexible platform and know-how in designing software for demanding bioinformatics environments will be tailored to meet the needs of oncology research at Bayer HealthCare Pharmaceuticals."

Financial and other terms were not disclosed.

MediSapiens is a startup bioinformatics firm based in Helsinki. It received $1 million in seed funding in the spring of 2010.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.